Cancer targeted nanoparticles specifically induce apoptosis in cancer cells and spare normal cells

Jagat R. Kanwar, Rupinder K. Kanwar, Ganesh Mahidhara, Chun Hei Antonio Cheung

Research output: Contribution to journalReview article

15 Citations (Scopus)

Abstract

Curing cancer is the greatest challenge for modern medicine and finding ways to minimize the adverse effects caused by chemotherapeutic agents is of importance in improving patient's physical conditions. Traditionally, chemotherapy can induce various adverse effects, and these effects are mostly caused by the non-target specific properties of the chemotherapeutic compounds. Recently, the use of nanoparticles has been found to be capable of minimizing these drug-induced adverse effects in animals and in patients during cancer treatment. The use of nanoparticles allows various chemotherapeutic drugs to be targeted to cancer cells with lower dosages. In addition to this, the use of nanoparticles also allows various drugs to be administered to the subjects by an oral route. Here, locked nucleic acid (LNA)-modified epithelial cell adhesion molecules (EpCAM), aptamers (RNA nucleotide), and nucleolin (DNA nucleotide) aptamers have been developed and conjugated on anti-cancer drug-loaded nanocarriers for specific delivery to cancer cells and spare normal cells. Significant amounts of the drug loaded nanocarriers (92±6%) were found to distribute to the cancer cells at the tumour site and more interestingly, normal cells were unaffected in vitro and in vivo. In this review, the benefits of using nanoparticle-coated drugs in various cancer treatments are discussed. Various nanoparticles that have been tried in improving the target specificity and potency of chemotherapeutic compounds are also described. Journal compilation

Original languageEnglish
Pages (from-to)5-14
Number of pages10
JournalAustralian Journal of Chemistry
Volume65
Issue number1
DOIs
Publication statusPublished - 2012 Feb 16

Fingerprint

Cells
Apoptosis
Nanoparticles
Pharmaceutical Preparations
Nucleotide Aptamers
Oncology
Chemotherapy
Cell Adhesion Molecules
Medicine
Curing
Tumors
Animals
Nucleotides
DNA

All Science Journal Classification (ASJC) codes

  • Chemistry(all)

Cite this

@article{50ced3654f3247dea3852071d38d6252,
title = "Cancer targeted nanoparticles specifically induce apoptosis in cancer cells and spare normal cells",
abstract = "Curing cancer is the greatest challenge for modern medicine and finding ways to minimize the adverse effects caused by chemotherapeutic agents is of importance in improving patient's physical conditions. Traditionally, chemotherapy can induce various adverse effects, and these effects are mostly caused by the non-target specific properties of the chemotherapeutic compounds. Recently, the use of nanoparticles has been found to be capable of minimizing these drug-induced adverse effects in animals and in patients during cancer treatment. The use of nanoparticles allows various chemotherapeutic drugs to be targeted to cancer cells with lower dosages. In addition to this, the use of nanoparticles also allows various drugs to be administered to the subjects by an oral route. Here, locked nucleic acid (LNA)-modified epithelial cell adhesion molecules (EpCAM), aptamers (RNA nucleotide), and nucleolin (DNA nucleotide) aptamers have been developed and conjugated on anti-cancer drug-loaded nanocarriers for specific delivery to cancer cells and spare normal cells. Significant amounts of the drug loaded nanocarriers (92±6{\%}) were found to distribute to the cancer cells at the tumour site and more interestingly, normal cells were unaffected in vitro and in vivo. In this review, the benefits of using nanoparticle-coated drugs in various cancer treatments are discussed. Various nanoparticles that have been tried in improving the target specificity and potency of chemotherapeutic compounds are also described. Journal compilation",
author = "Kanwar, {Jagat R.} and Kanwar, {Rupinder K.} and Ganesh Mahidhara and Cheung, {Chun Hei Antonio}",
year = "2012",
month = "2",
day = "16",
doi = "10.1071/CH11372",
language = "English",
volume = "65",
pages = "5--14",
journal = "Australian Journal of Chemistry",
issn = "0004-9425",
publisher = "CSIRO",
number = "1",

}

Cancer targeted nanoparticles specifically induce apoptosis in cancer cells and spare normal cells. / Kanwar, Jagat R.; Kanwar, Rupinder K.; Mahidhara, Ganesh; Cheung, Chun Hei Antonio.

In: Australian Journal of Chemistry, Vol. 65, No. 1, 16.02.2012, p. 5-14.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Cancer targeted nanoparticles specifically induce apoptosis in cancer cells and spare normal cells

AU - Kanwar, Jagat R.

AU - Kanwar, Rupinder K.

AU - Mahidhara, Ganesh

AU - Cheung, Chun Hei Antonio

PY - 2012/2/16

Y1 - 2012/2/16

N2 - Curing cancer is the greatest challenge for modern medicine and finding ways to minimize the adverse effects caused by chemotherapeutic agents is of importance in improving patient's physical conditions. Traditionally, chemotherapy can induce various adverse effects, and these effects are mostly caused by the non-target specific properties of the chemotherapeutic compounds. Recently, the use of nanoparticles has been found to be capable of minimizing these drug-induced adverse effects in animals and in patients during cancer treatment. The use of nanoparticles allows various chemotherapeutic drugs to be targeted to cancer cells with lower dosages. In addition to this, the use of nanoparticles also allows various drugs to be administered to the subjects by an oral route. Here, locked nucleic acid (LNA)-modified epithelial cell adhesion molecules (EpCAM), aptamers (RNA nucleotide), and nucleolin (DNA nucleotide) aptamers have been developed and conjugated on anti-cancer drug-loaded nanocarriers for specific delivery to cancer cells and spare normal cells. Significant amounts of the drug loaded nanocarriers (92±6%) were found to distribute to the cancer cells at the tumour site and more interestingly, normal cells were unaffected in vitro and in vivo. In this review, the benefits of using nanoparticle-coated drugs in various cancer treatments are discussed. Various nanoparticles that have been tried in improving the target specificity and potency of chemotherapeutic compounds are also described. Journal compilation

AB - Curing cancer is the greatest challenge for modern medicine and finding ways to minimize the adverse effects caused by chemotherapeutic agents is of importance in improving patient's physical conditions. Traditionally, chemotherapy can induce various adverse effects, and these effects are mostly caused by the non-target specific properties of the chemotherapeutic compounds. Recently, the use of nanoparticles has been found to be capable of minimizing these drug-induced adverse effects in animals and in patients during cancer treatment. The use of nanoparticles allows various chemotherapeutic drugs to be targeted to cancer cells with lower dosages. In addition to this, the use of nanoparticles also allows various drugs to be administered to the subjects by an oral route. Here, locked nucleic acid (LNA)-modified epithelial cell adhesion molecules (EpCAM), aptamers (RNA nucleotide), and nucleolin (DNA nucleotide) aptamers have been developed and conjugated on anti-cancer drug-loaded nanocarriers for specific delivery to cancer cells and spare normal cells. Significant amounts of the drug loaded nanocarriers (92±6%) were found to distribute to the cancer cells at the tumour site and more interestingly, normal cells were unaffected in vitro and in vivo. In this review, the benefits of using nanoparticle-coated drugs in various cancer treatments are discussed. Various nanoparticles that have been tried in improving the target specificity and potency of chemotherapeutic compounds are also described. Journal compilation

UR - http://www.scopus.com/inward/record.url?scp=84857006930&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857006930&partnerID=8YFLogxK

U2 - 10.1071/CH11372

DO - 10.1071/CH11372

M3 - Review article

AN - SCOPUS:84857006930

VL - 65

SP - 5

EP - 14

JO - Australian Journal of Chemistry

JF - Australian Journal of Chemistry

SN - 0004-9425

IS - 1

ER -